# Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

Source: https://onco.cc/trials/nct07680439/  
OnCo record `nct07680439` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BCB-276 in diffuse midline glioma, h3 k27-altered, run by BrainChild Bio, Inc, now recruiting.

## Summary

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). is a phase 2 interventional study registered as NCT07680439 by BrainChild Bio, Inc, with 75 participants planned, started 2026-08 and due to reach its primary completion in 2028-10. Interventions recorded: BCB-276. Conditions listed: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07680439
- Phase: 2
- Setting: A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma
- Sponsor: BrainChild Bio, Inc
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07680439: https://clinicaltrials.gov/study/NCT07680439

## Connected records

- cancers: [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/)
- drugs: [BCB-276](https://onco.cc/drugs/bcb-276/)

---
JSON: https://onco.cc/api/v1/entities/nct07680439.json